Correction: Bulletin from the Extraordinary General Meeting in Nexam Chemical Holding AB (publ) on January 19 2026

At an extraordinary general meeting on 19 January 2026 Nexam Chemical approved a rights issue expected to raise approximately SEK 51.8 million before issue costs (correction from an earlier SEK 58.1m figure). The issue allocates one subscription right per existing share (15 rights to subscribe for 4 new shares) at SEK 2.40 per share, for up to 21,577,544 new shares with a subscription period of 26 January–9 February 2026; the EGM also authorised issuance of shares to guarantors (at VWAP but not below SEK 2.40) and an over-allotment of up to 6,250,000 shares at SEK 2.40 to top guarantors. These measures secure short-term financing but will dilute existing shareholders if fully exercised.

Analysis

Market structure: The SEK 51.8m rights issue (SEK 2.40/share, max 21.58m new shares plus 6.25m over-allotment) materially increases float and creates near-term supply pressure; guarantor allocations and VWAP-floor issuance incentivize post-listing selling which favors short-term bears. Winners: guarantors/top guarantors (fee/compensation upside) and buyers of newly issued shares if proceeds are deployed into commercial scale‑ups; losers: existing retail holders facing ~>20–40% immediate dilution risk and any leveraged holders. Cross-asset: expect increased equity volatility in small-cap Swedish specialty-chemicals, mild widening of credit spreads for similarly sized issuers, and no material FX/commodity impact beyond sector raw-material pass-throughs.

Risk assessment: Tail risks include failed subscription triggering cash shortfall or forced deep dilution (>30%) from guarantee shares, and operational risk if proceeds are misallocated (R&D to non-revenue projects). Immediate (days) risk centers on settlement and guarantor selling (Jan 26–Feb 9 subscription window, monitor allotment news through Feb 12); short-term (weeks/months) risk is liquidity shock and margin selling; long-term (6–24 months) depends on commercialization milestones and revenue ramp. Hidden dependency: the VWAP floor links guarantor compensation to market price, creating cliff selling if price < target; catalyst set pieces are subscription uptake figures, AGM updates, and quarterly sales guidance.

Trade implications: Primary direct play is a tactical short of Nexam Chemical (small sized, 2–4% portfolio) into the subscription period to capture anticipated dilution-driven downside; cover after full allotment and first 10 trading days post-listing (target 20–35% downside). If liquidity precludes outright short, use put spreads or short small-cap Swedish materials ETF as proxy. Longer-term selective long only if post-rights cash deployment is transparent and revenue CAGR >30% is demonstrated within 12–18 months.

Contrarian angles: Consensus will likely be negative on dilution, but market may underprice scenario where SEK ~52m accelerates commercialization—if management converts capital into recurring contracts, equity could re-rate 2–4x from low base over 12–24 months. Historical parallels: small-cap rights issues often drop 20–40% then recover if execution is flawless; risk is execution is rarely flawless here. Unintended consequence: heavy guarantor selling could create a buying opportunity for patient, well‑funded strategics seeking tech IP; track any inbound M&A chatter within 3–6 months.

Key Decisions for Investors

• Establish a tactical short position in Nexam Chemical (size 2–4% of book) between now and Feb 9, 2026; set take‑profit at 25–35% downside and hard stop at 15% adverse move above SEK 3.10 (use liquid equivalents if direct shorting impossible).
• If Nexam trades < SEK 1.80 within 1–3 months post-rights and company publishes a clear use-of-proceeds plan tied to revenue-generating contracts, accumulate a contrarian long (1–3% position) and hold 12–24 months, target 2–3x capital if milestones met.
• If options are available/ liquid, buy a 2-month put spread sized 0.5–1% notional (long SEK 2.40 put, short SEK 1.60 put) to hedge existing exposure or profit from elevated volatility through Feb–Mar 2026; enter if IV >40%.
• Overweight larger, liquid specialty-chemicals to reduce idiosyncratic risk: add 2% weight to Covestro (1COV.DE) and 2% to BASF (BAS.DE) as defensive sector exposure while avoiding small-cap financing risk over next 6–12 months.
• Trigger-based monitoring: if subscription uptake reported <50% by Feb 12, move from tactical short to aggressive short/increase exposure by 50% (indicating higher dilution/default risk); if uptake >80% and management publishes detailed commercialization milestones within 30 days, reduce short by 50% and reassess long entry criteria.